BridgeBio

Est. 2014Public Company818 Employees
Employees
~818
Founded
2014

About BridgeBio

BridgeBio identifies, develops, and provides transformative therapies for genetic disorders. Across the globe, millions suffer from genetic conditions, yet limited patient groups and a hesitancy within the industry to pursue early-stage research mean that many lack available treatments. Our mission is to close this divide—between commercial viability and scientific potential, between patients and hope. BridgeBio forges a link from significant progress in genetic research to individuals with unaddressed needs, powered by the entrepreneurial drive necessary to deliver life-altering medicines with utmost speed. BridgeBio is equally dedicated to cultivating leaders and creating medications. We seek individuals whose enthusiasm for developing life-changing treatments will foster direct participation and unwavering pursuit of innovative answers when confronted with challenges.

Key Facts
Approximately 818 employees globally
Operates in Biotechnology Research
Founded in 2014

Executive Leadership Team

EC
Erika Chiles-George
Executive Director, Head of Pricing and Contracting
Since 2023
Julie Miller Everett
Julie Miller Everett
Chief Business Officer
Since 2023
Kevin Maloy
Kevin Maloy
Executive Director, Field Reimbursement
Since 2023
Matt Outten MBA, ALM, CPC
Matt Outten MBA, ALM, CPC
Chief Executive Officer, QED Therapeutics, Oncology, Chief Commercial Officer, BridgeBio
Since 2019
NK
Neil Kumar
Chief Executive Officer and Founder
Since 2014

Organizational Chart — Preview

Powered by OrgKonnect
Live from OrgKonnect — bizkonnect.ai
See the Full Org Chart with Contact Details
Unlock reporting lines, direct contacts, connection paths, and business insights for all BridgeBio's employees

BridgeBio Executive Leadership Team

EC
Erika Chiles-George
Executive Director, Head of Pricing and Contracting
Since 2023
Julie Miller Everett
Julie Miller Everett
Chief Business Officer
Since 2023
Kevin Maloy
Kevin Maloy
Executive Director, Field Reimbursement
Since 2023
Matt Outten MBA, ALM, CPC
Matt Outten MBA, ALM, CPC
Chief Executive Officer, QED Therapeutics, Oncology, Chief Commercial Officer, BridgeBio
Championing great science A confluence of breakthroughs in genome sequencing, molecular biology, and patient information databases and registries give us the opportunity to make therapeutic leaps against genetic disease. BridgeBio finds great science where the mechanism of a disease is well-understood and develops medicines that target those diseases at their source. A new type of biotech company We are working to create a bridge between promising genetic research and actual medicines with the people, platform, and processes needed to advance multiple individual therapies simultaneously. Our decentralized subsidiary model lets us distribute shared central resources while remaining hyper-focused on developing therapies for each disease. Built for speed + scale Our model creates efficiency, rigor, and scale, empowering our teams to make objective, data-driven decisions quickly across multiple programs. In just three years, BridgeBio has more than 15 drug programs for 20 genetic diseases - which we believe reduces the traditional biopharma process by years.
Since 2019
NK
Neil Kumar
Chief Executive Officer and Founder
Since 2014

BridgeBio Org Chart & Organizational Structure

BridgeBio is a biopharmaceutical company founded and led by Neil Kumar, who serves as its Chief Executive Officer and Founder. The organization is structured around a Sales function, which encompasses the sub-functions of Sales Development and Pricing and Quoting. Within the Sales Development sub-function, Business Development is a further focus area. Key leadership within BridgeBio’s Sales and related functions includes Matt Outten, who holds the dual role of Chief Executive Officer at QED Therapeutics Oncology and Chief Commercial Officer at BridgeBio; Kevin Maloy, serving as Executive Director of Field Reimbursement; Julie Miller Everett, who is the Chief Business Officer; and Erika Chiles-George, who is the Executive Director and Head of Pricing and Contracting.

Frequently Asked Questions

7 questions

What does BridgeBio's BizKonnect profile actually show?

An overview with industry, headquarters, employee count, and public/private status; an About section describing the business; Key Facts; an Executive Leadership Team list; and a preview of the OrgKonnect's GenAI-powered org chart built by BizKonnect.

Can I see BridgeBio's complete org chart here, or just part of it?

You get a free preview of the top-level structure and business units, generated by BizKonnect's GenAI-powered org chart engine; the full chart with reporting lines and direct contacts unlocks via "Get Free Access to Full Org Chart."

How is BridgeBio's organizational structure mapped on BizKonnect?

BridgeBio's hierarchy is broken into functional departments IT, Finance, Commercial Sales, Operations and distinct business units, with GenAI-powered interactive org charts mapping reporting lines directly up to the CXOs.

Does the page show which executive oversees which function?

Yes, functions like Finance, Sales, Operations, and Information Technology are each tied to a named executive and their title, based on BridgeBio's reported leadership structure.

Is executive tenure information included?

Each leader's profile shows how long they've held their role, marked "Since [year]," so you can see how recently BridgeBio's leadership team has changed.

How do BridgeBio's GenAI-powered org charts support Account-Based Marketing (ABM)?

The visual maps break down multi-person buying centers within BridgeBio, helping ABM teams identify actual budget owners, understand peer reporting relationships, and run multi-threaded outreach without getting stuck behind gatekeepers.

Are there other companies worth researching alongside BridgeBio?

Yes, a "Similar Companies" section links to comparable organizations in the same industry, generated by GenAI industry clustering to help expand your target account lists.